PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

PuraMed BioScience (OTCBB:PMBS), announced today that a clinical study of LipiGesic™ M has been completed.

The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.

"We are very pleased to announce that our clinical study on LipiGesic™ M has been completed," said PuraMed BioScience CEO Russell Mitchell. "Even though this study was not a requirement for us to market LipiGesic™ M, we feel it may provide us with objective scientific data we may be able to employ to help describe the efficacy of the product, how it should be properly used and perhaps new labeling opportunities that could increase product visibility not only to the medical community, but the general public as well. The completion of this study is yet another milestone that we have achieved based on the model we laid out in our business plan.  We expect to continue to be on time and on target as we prepare for the national retail launch of LipiGesic™ M."